AbbVie made a milestone payment to Dragonfly Therapeutics, a clinical stage biotechnology company developing novel immunotherapies, following dosing of the first patient in a clinical trial to evaluate ABBV-303, a solid tumor targeting TriNKET. ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie’s budigalimab in solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
- Regenxbio expects cash to fund operations into 2H25
- AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
- Genmab, AbbVie announce FDA priority review for sBLA
- Truist biotech analysts hold an analyst/industry conference call